HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis CEO Jimenez Highlights OTC Switches, Consumer Acquisitions

This article was originally published in The Tan Sheet

Executive Summary

Incoming Novartis CEO Joe Jimenez plans to expand the Swiss firm's consumer health division over the next few years after he takes the reins from his predecessor Daniel Vasella

You may also be interested in...



Novartis Makes Room For OTC Division Head On Executive Committee

Novartis gives its OTC unit a direct line to the chief executive in an organizational realignment designed to strengthen and streamline the consumer businesses.

People In Brief

P&G's Lafley joins private equity firm: Clayton, Dubilier & Rice welcomes former Procter & Gamble CEO A.G. Lafley as a special partner, the firm said April 7. Lafley held various positions with P&G for 32 years, including CEO for nine years, before retiring in 2009. "His experience building strong business operations, promoting innovation, and spurring growth across global markets enhances our value-creation capabilities," said CD&R President and CEO Donald J. Gogel. Lafley said he was attracted to CD&R because of its "successful history of building long-term value by improving the operational performance of its portfolio businesses exemplifies the positive role that private equity can play in the economy." Among the firm's diverse investments are companies in fields matching Lafley's industry-specific experience, such as Sally Beauty Holdings

Novartis To Launch Nycomed's PPI Pantoloc Control In 14 European Countries

Novartis will launch the OTC proton pump inhibitor Pantoloc Control (pantoprazole 20 mg) in 14 European countries in the second quarter of 2010 under a co-marketing agreement with the product's originator Nycomed

Related Content

Topics

UsernamePublicRestriction

Register

RS135142

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel